X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The collaboration aims to leverage Nona's proprietary Harbour Mice H2L2 (two light and two heavy chains) platform to accelerate the development of Antibody-Drug Conjugates targeting cancer.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Large molecule
Partner/Sponsor/Collaborator: Boostimmune
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 26, 2024
Details:
Under the agreement, Pfizer obtains right for the global clinical development and commercialization of Nona Biosciences' MSLN-targeted ADC, HBM9033, that specifically targets human MSLN, a tumor-associated antigen (TAA) upregulated in various solid tumors.
Lead Product(s): HBM9033
Therapeutic Area: Oncology Product Name: HBM9033
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Pfizer Inc
Deal Size: $1,103.0 million Upfront Cash: $53.0 million
Deal Type: Licensing Agreement December 14, 2023
Details:
The collaboration aims to accelerate the process of antibody discovery and drug development based on the Harbour Mice® antibody technology platform of Nona Biosciences.
Lead Product(s): Undisclosed
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Recipient: Evive Biotech
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration December 10, 2023
Details:
Under the collaboration, Lycia will leverage Nona's proprietary Harbour Mice® HCAb fully human antibody transgenic mice platform to discover novel antibodies for its LYTAC protein degrader therapeutics.
Lead Product(s): Undisclosed
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Large molecule
Partner/Sponsor/Collaborator: Lycia Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration December 04, 2023
Details:
Under the collaboration, Nona Biosciences will integrate GeneQuantum's exclusive and innovative iLDC and iGDC platforms, with its Harbour Mice® platform and cutting-edge technologies, to advance the early discovery of next-generation bioconjugates.
Lead Product(s): Bioconjugate
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Recipient: GeneQuantum Healthcare
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration November 13, 2023
Details:
By harnessing the immense expertise and resources of both companies, the collaboration aims to accelerate the development of innovative therapeutics for immunological disorders with highly unmet needs.
Lead Product(s): Undisclosed
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Ingenia Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration October 13, 2023
Details:
Under the expanded collaboration, BeiGene will be granted access to Nona Biosciences' proprietary fully human transgenic mice platform Harbour Mice and will extend to the Harbour Mice® HCAb platform to further improve therapeutic antibody discovery efficiency and flexibility.
Lead Product(s): Undisclosed
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: BeiGene
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Expanded Collaboration September 14, 2023
Details:
HBM9033 is an ADC drug candidate that specifically targets human mesothelin (MSLN), an upregulated tumor associated antigen in various solid tumors, including mesothelioma, ovary cancer, lung cancer, breast cancer, and pancreatic cancers.
Lead Product(s): HBM9033
Therapeutic Area: Oncology Product Name: HBM9033
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 28, 2023
Details:
HBM9161 (batoclimab) is a fully human anti-FcRn mAb, blocks FcRn-IgG interactions, accelerating the degradation of autoantibodies and leads to the treatment of pathogenic IgG-mediated autoimmune diseases like Generalized Myasthenia Gravis.
Lead Product(s): Batoclimab
Therapeutic Area: Immunology Product Name: HBM9161
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 29, 2023
Details:
HBM1020 is a first-in-class fully human monoclonal antibody generated from Harbour Mice® H2L2 transgenic mice platform, targeting B7H7/HHLA2, which being investigated for patients with advanced solid tumors.
Lead Product(s): HBM1020
Therapeutic Area: Oncology Product Name: HBM1020
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 04, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
